Lyell Immunopharma, Inc. (LYEL) Price Prediction 2026–2050

Lyell Immunopharma, Inc. is a clinical-stage cell therapy company that develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The lead product candidate is rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development.

A second pivotal PiNACLE-H2H trial is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting. Lyell also has LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.

The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma, Inc. (LYEL) trades at $12.92 per share and has a market capitalization of $301.48M, ranking 3281 by market cap.

The current price and market position set the stage for a detailed forecast path. The 2026 forecast shows a min of $11.61, an average of $12.92, and a max of $18.13 with ROI of 0 and sentiment NEUTRAL.

Beyond 2026, the forecast presents a trajectory with periods of upside and occasional downside, culminating in higher price levels and bullish sentiment in the later years, including notable targets through 2033–2050.

The multi-year forecast shows a path of growth with a shift to bullish sentiment beginning in the early- to mid-2030s. In 2033, the avg is $18.41 with a max of $33.55 and ROI of 42.5% (sentiment BULLISH). The following year, 2034, features an avg of $19.24 with a max of $35.90 and ROI of 48.9% (BULLISH).

Longer range projections show strong upside: 2040 with an avg of $25.52, max $53.16, ROI 97.5% (BULLISH); and 2050 with an avg of $32.56, max $74.89, ROI 152% (BULLISH).

In the near term, the forecast includes years with negative ROI, such as 2029 with ROI -4.1% and 2030 with ROI -5.2%, illustrating that downside risk remains possible. Despite those dips, the overall longer-horizon path points to substantial upside potential in the 2030s to 2050, aligned with the higher-year targets and bullish sentiment.